Evaluation of erythroblast macrophage protein related to erythroblastic islands in patients with hematopoietic stem cell transplantation

Xiaolu Mao, Xiaoyan Shi, Feng Liu, Guining Li and Lihua Hu

Abstract

Background: Hematopoietic evaluation of the patients after Hematopoietic stem cell transplantation (HSCT) is very important. Erythroblast macrophage protein (Emp) is a key protein with function in normal differentiation of erythroid cells and macrophages. Emp expression correlates with erythroblastic island formation, a process widely believed to be associated with hematopoiesis in bone marrow. We aimed to investigate the hematopoietic function of bone marrow from 46 HSCT patients and 16 inpatients with severe anemia applied to the treatment of EPO by measuring Emp expression level.

Methods: Emp mRNA and protein expression levels in mononuclear cells of bone marrow and peripheral blood samples were detected by RT-PCR and Western blotting method respectively.

Results: While hematopoiesis occurs in bone marrow, Emp expression level was elevated and more erythroblastic islands were found, and Emp is upregulated in bone marrow in response to erythropoietin (EPO) treatment.

Conclusions: Emp expression correlates with erythroblastic island formation and has an important function for bone marrow hematopoiesis. Emp could be a potential biomarker for hematopoietic evaluation of HSCT patients.

Keywords: Erythroblast macrophage protein, Cancer, Hematopoietic stem cell transplantation, Hematopoiesis, Erythroblastic island

Background

The erythroblastic island is a distinct anatomic unit which consists of a central macrophage surrounded by erythroid cells. These islands are present at various stages of differentiation in the fetal liver and the adult bone marrow, and have a key role in erythroid cell proliferation and differentiation [1-4]. Gregory and Eaves found that the erythroid cells differentiated through morphologically defined stages of erythroid progenitors, proerythroblasts, basophilic erythroblasts, polychromatophilic erythroblasts, and orthochromatophilic erythroblasts [5,6]. The orthochromatophilic erythroblasts then underwent enucleation by extruding their nucleus and became reticulocytes, further expelling all organelles and detaching from their microenvironment to form mature circulating erythrocytes. Over the course of erythroid differentiation, erythroblasts displayed a gradual decrease in cell size and an increase in hemoglobin concentration [7]. The major changes of erythroid cells occurred in erythroblastic island, which correlate with the hematopoiesis of bone marrow. Despite recent advances, the mechanism of erythroblast maturation remains poorly understood. Previous reports showed that within erythroblastic islands, both erythroblast-macrophage and erythroblast-erythroblast maturation occurred by extensive interactions [1,2,8-12]. Interestingly, only a few molecules have been definitively shown to enhance the formation of erythroblastic islands. The adhesive interaction involved α4β1 integrin and vascular cell adhesion molecule-1 (VCAM-1) were first identified in erythroblasts and macrophages, respectively [13]. Recently, the role of ICAM-4 in erythroblastic island formation has been clearly documented by gene targeting in-vivo studies [14,15]. Emp was initially
identified as a mediator of erythroblast-macrophage interactions during erythroid differentiation [1,2,8,9]. More recently, it was thought that Emp had an important role in erythroblastic island formation [8,16,17]. Using a transplant combination from Emp null fetal liver cells to lethally irradiated wild-type sibling mice, Soni et al. found that loss of Emp function in erythroid cells resulted in impaired proliferation and terminal differentiation[18]. These findings suggest that Emp protein might be a potential molecular marker for hematopoietic evaluation.

Hematopoietic stem cell transplantation (HSCT) is the transplantation of stem cells derived from the bone marrow or blood [19]. Stem cell transplantation is a medical procedure used in the fields of hematology and oncology. Increase in the number of erythroblastic islands in bone marrow always suggests a successful HSCT. However, no clinical correlation between Emp levels and hematopoiesis has been established. In this study, we evaluated hematopoietic function of bone marrow in HSCT patients through the change of Emp expression before and after HSCT. Based on our data, we suggest that Emp is a potential biomarker for hematopoietic evaluation of HSCT patients.

**Methods**

**Patient characteristics of HSCT**

The use of human cord blood and peripheral blood was approved by Medical Ethical Committee of the Tongji Medical College. Approval was granted in accordance with Chinese legislations, and written informed consent was obtained from all participants, in accordance with the guidelines of the Chinese Ministry of Health. HSCT recipients at the HSCT program of the Hematology and Hemotherapy Discipline at Tongji Medical College, Huazhong University of Science and Technology were prospectively enrolled in this trial. Forty-six patients, HSCT recipients from September 2008 to December 2009, were eligible for the study. Thirty-one patients underwent allogeneic HSCTs, and 15 patients received autologous HSCTs. In the allogeneic HSCT group, all patients received HSCTs from a human leukocyte antigen (HLA) of identical donor, and no patient received a T-cell depleted HSCT. Demographic details for all 46 patients are shown in Table 1.

Peripheral blood and bone marrow were taken from HSCT recipients at the point of 30, 90, and 180 days, respectively. Before HSCT, all patient samples of peripheral blood and bone marrow were acted as the second control group, and that 10 donors constituted the first control group. Samples were processed for peripheral blood and bone marrow smears, and isolation of mononuclear cells.

**Isolation of mononuclear cells in peripheral blood and bone marrow**

Heparinized (10 IU/mL) peripheral blood and bone marrow was layered on a Ficoll-Hypaque discontinuous gradient system (Sigma) and centrifuged at 1200 × g for 30 min. The mononuclear cells at the interface of plasma and Ficoll-Hypaque were collected and resuspended in serum-free dulbecco’s modified eagle medium (DMEM). Then the quantity (A) of mononuclear cells were detected by the blood cell analyzer (Beckman Coulter), and their smears were examined by Wright/Giemsa staining (Maker Biotechnology Co., China) for the erythroblastic cell ratio (B%) of mononuclear cells. The erythroblastic cell of number was calculated using the equation: erythroblastic cells (× 10^9/L) = A(× 10^9/L) × B%

**Morphology**

The morphology of peripheral blood and bone marrow cells was examined by Wright/Giemsa staining. In addition to using blood cell analyzer, cells were directly

| Table 1 Patient characteristics, HSCT type, underlying disease, and immunosuppressive regimens used before HSCT |
|---------------------------------------------------------------|
| **Gender** | n (%) |
| Female | 20 (43.5) |
| Male | 26 (56.5) |
| **Age** | Years (range) |
| Mean | 32 (18–37) |
| **HSCT** | n (%) |
| Allogeneic | 31 (67.4) |
| Autologous | 15 (32.6) |
| **Underlying disease** | n (%) |
| Chronic myelogenous leukemia | 26 (56.5) |
| Acute myelogenous leukemia | 8 (17.4) |
| Multiple myeloma | 6 (13.1) |
| Hodgkin’s lymphoma | 3 (6.5) |
| Severe aplastic anemia | 3 (6.5) |
| Immunosuppressive conditioning regimen | n (%) |
| Busulfan and melphalan | 30 (65.2) |
| Busulfan and cyclophosphamide | 4 (8.7) |
| Total body irradiation and melphalan | 3 (6.5) |
| Total body irradiation and cyclophosphamide | 3 (6.5) |
| Other | 6 (13.1) |
smeared onto glass plate in an appropriate cell concentration (10 μL blood or bone marrow) and stained with Wright/Giemsa solution. The morphology of blood cells was observed under microscope and at least 200 blood cells with nucleus were counted to determine the ratio of erythroblastic cell in peripheral blood, or the hyperplastic degree in bone marrow.

Semi-quantitative RT-PCR
Mononuclear cells in bone marrow and peripheral blood samples were adjusted to the same quantity (1 × 10⁶ cells in PBS). Total RNA was extracted from the cells and single strand cDNA synthesis was performed by using Blood RNA extraction kit (QIAGEN, Hilden, Germany) and moloney murine leukemia virus-reverse transcription kit (SuperSciptII, Life Technologies, Inc.) according to the manufacturer’s directions. PCR primers used for Emp and β-actin mRNA detection are as follows: Emp sense 5’-ACCCGACCCTCAAGGTGCC-3’, antisense 5’-GTGGCCG TCTCAGCCTCTT-3’, β-actin sense 5’TTC CTGGGCATGGAGTCT-3’, antisense 5’TGATCTT CATTGTGCTGGGTG-3’. The gene expression levels were normalized by β-actin.

Western blot
Cells were lysed with lysis buffer (20 mMTris–HCl pH 7.8, 1 mM EDTA, 50 mM sodium chloride, and 0.5% NP-40), and protein concentration was determined by BCA assay kit (Pierce, USA). Western blot analysis was carried out as directions of manufacturer (Cell signaling Biotech). Antibodies against human Emp (Abcam plc. USA. ab65239) and β-actin (Cell signaling Biotech, USA) were used. Results were visualized with horseradish peroxidase-conjugated secondary antibodies (Sigma, USA; 1:1000) and enhanced chemiluminescence.

EPO treatment
Use of erythropoietin (EPO) hormone as an anti-apoptotic permitted survival of erythroid progenitors from erythrocyte colony-forming unit (CFU-E) through early proerythroblast stages of differentiation [20]. A total of 16 inpatients with severe anemia were applied to the treatment of EPO (rhu EPO, 75 u per kg, 3 times weekly, subcutaneous). Pre- and post-EPO treatment bone marrow samples were obtained for morphology and Emp expression analysis. There were six women and 10 men among 16 inpatients, and their mean age was 33 years. The mean hemoglobin level in 16 inpatients was 46.3 ± 2.3 g/L before EPO treatment. Erythroblastic islands were not visible in their bone marrow. The inpatients characteristics before EPO treatment are shown in Table 2.

Statistical analysis
Statistical analysis between groups was performed using Student t-test. Results were considered statistically significant if P values were <0.05.

| Groups | Peripheral blood | Bone marrow |
|--------|------------------|-------------|
|        | MWBCs (×10⁹/L)   | MERw (%)    | MMCS (×10⁹/L) | MERm (%) | BMHD | MIQAS | MMCS (×10⁹/L) | MERm (%) |
| The first control | 5.7 ± 1.3 | 1.1 ± 0.4 | 2.7 ± 1.5 | 1.4 ± 0.5 | Activity | 21.4 ± 4.5 | 12.8 ± 2.5 | 48 ± 4.3 |
| The second control | 2.1 ± 0.7 | 6 ± 1.2 | 1.7 ± 0.6 | 10.3 ± 1.7 | Low or extremely low | 3.2 ± 1.4a | 5.3 ± 1.4a | 16.7 ± 1.6a |
| 30 days after HSCT | 2.5 ± 1.0a | 13.6 ± 1.6a | 1.5 ± 0.4 | 17.8 ± 1.9a | Activity | 43.3 ± 4.1ab | 6.6 ± 1.7a | 23.5 ± 1.2a |
| 90 days after HSCT | 3.2 ± 1.2a | 15.4 ± 1.8a | 2.2 ± 0.7 | 19.7 ± 1.4a | More activity | 46.2 ± 3.6abc | 10.4 ± 1.5a | 31.2 ± 1.8a |
| 180 days after HSCT | 3.0 ± 1.1a | 14.2 ± 1.5a | 2.1 ± 0.8 | 18.5 ± 1.6a | Activity | 44.7 ± 4.2abc | 8.8 ± 1.2a | 33.4 ± 1.1a |

Table 2 The patient characteristics before EPO treatment

| Gender | n (%) |
|--------|-------|
| Female | 6 (37.5) |
| Male   | 10 (62.5) |

Table 3 Characteristics of morphology before or after HSCT

| Groups | Peripheral blood | Bone marrow |
|--------|------------------|-------------|
|        | MWBCs (×10⁹/L)   | MMCS (×10⁹/L) | MERm (%) | BMHD | MIQAS | MMCS (×10⁹/L) | MERm (%) |
| The first control | 5.7 ± 1.3 | 1.1 ± 0.4 | 2.7 ± 1.5 | 1.4 ± 0.5 | Activity | 21.4 ± 4.5 | 12.8 ± 2.5 | 48 ± 4.3 |
| The second control | 2.1 ± 0.7 | 6 ± 1.2 | 1.7 ± 0.6 | 10.3 ± 1.7 | Low or extremely low | 3.2 ± 1.4a | 5.3 ± 1.4a | 16.7 ± 1.6a |
| 30 days after HSCT | 2.5 ± 1.0a | 13.6 ± 1.6a | 1.5 ± 0.4 | 17.8 ± 1.9a | Activity | 43.3 ± 4.1ab | 6.6 ± 1.7a | 23.5 ± 1.2a |
| 90 days after HSCT | 3.2 ± 1.2a | 15.4 ± 1.8a | 2.2 ± 0.7 | 19.7 ± 1.4a | More activity | 46.2 ± 3.6abc | 10.4 ± 1.5a | 31.2 ± 1.8a |
| 180 days after HSCT | 3.0 ± 1.1a | 14.2 ± 1.5a | 2.1 ± 0.8 | 18.5 ± 1.6a | Activity | 44.7 ± 4.2abc | 8.8 ± 1.2a | 33.4 ± 1.1a |

Table 3 Characteristics of morphology before or after HSCT

| Groups | Peripheral blood | Bone marrow |
|--------|------------------|-------------|
|        | MWBCs (×10⁹/L)   | MMCS (×10⁹/L) | MERm (%) | BMHD | MIQAS | MMCS (×10⁹/L) | MERm (%) |
| The first control | 5.7 ± 1.3 | 1.1 ± 0.4 | 2.7 ± 1.5 | 1.4 ± 0.5 | Activity | 21.4 ± 4.5 | 12.8 ± 2.5 | 48 ± 4.3 |
| The second control | 2.1 ± 0.7 | 6 ± 1.2 | 1.7 ± 0.6 | 10.3 ± 1.7 | Low or extremely low | 3.2 ± 1.4a | 5.3 ± 1.4a | 16.7 ± 1.6a |
| 30 days after HSCT | 2.5 ± 1.0a | 13.6 ± 1.6a | 1.5 ± 0.4 | 17.8 ± 1.9a | Activity | 43.3 ± 4.1ab | 6.6 ± 1.7a | 23.5 ± 1.2a |
| 90 days after HSCT | 3.2 ± 1.2a | 15.4 ± 1.8a | 2.2 ± 0.7 | 19.7 ± 1.4a | More activity | 46.2 ± 3.6abc | 10.4 ± 1.5a | 31.2 ± 1.8a |
| 180 days after HSCT | 3.0 ± 1.1a | 14.2 ± 1.5a | 2.1 ± 0.8 | 18.5 ± 1.6a | Activity | 44.7 ± 4.2abc | 8.8 ± 1.2a | 33.4 ± 1.1a |

*P < 0.05, vs. the first control group.

Table 2 The patient characteristics before EPO treatment

| Gender | n (%) |
|--------|-------|
| Female | 6 (37.5) |
| Male   | 10 (62.5) |

The patient characteristics before EPO treatment

| Gender | n (%) |
|--------|-------|
| Female | 6 (37.5) |
| Male   | 10 (62.5) |

EPO treatment
Use of erythropoietin (EPO) hormone as an anti-apoptotic permitted survival of erythroid progenitors from erythrocyte colony-forming unit (CFU-E) through early proerythroblast stages of differentiation [20]. A total of 16 inpatients with severe anemia were applied to the treatment of EPO (rhu EPO, 75 u per kg, 3 times weekly, subcutaneous). Pre- and post-EPO treatment bone marrow samples were obtained for morphology and Emp expression analysis. There were six women and 10 men among 16 inpatients, and their mean age was 33 years. The mean hemoglobin level in 16 inpatients was 46.3 ± 2.3 g/L before EPO treatment. Erythroblastic islands were not visible in their bone marrow. The inpatients characteristics before EPO treatment are shown in Table 2.
Results

Analysis of morphology

To analyze the hematopoietic function of bone marrow in different groups, morphology analysis was conducted in all samples. In the bone marrow donor group, the MWBCs (Mean White Blood Cells) is 5.7 ± 1.3 × 10⁹/L and the MMCs (Mean Mononuclear Cells) is 2.7 ± 1.5 × 10⁹/L in peripheral blood. The MWBCs and MMCs in peripheral blood from inpatients pre- and post-HSCT were lower than that in the peripheral blood from bone

---

**Figure 1** The hyperplastic degree and morphology of erythroblastic islands in bone marrow. (A) The bone marrow hyperplastic degree. Extremely low (a), low (b), active (c), more active (d). The images were taken under 100× magnification. (B) Morphology of bone marrow erythroblastic islands was shown under 100× (e), 400× (f), and 1,000× magnification (g). The larger arrow pointed to the macrophage and the smaller ones indicated erythroblasts.

**Figure 2** Emp expression levels in peripheral blood and bone marrow. (A) Emp protein levels in bone marrow in pre- and post-HSCT groups. (B) Emp mRNA levels in peripheral blood, bone marrow and Emp protein-positive bone marrow. (C) The mean gray-scale ratio of Emp to β-actin in peripheral blood and bone marrow from the bone marrow donor group, pre-HSCT group and day 30, 90, or 180 post-HSCT groups. These data are representative of three independent experiments. n = 3. *P < 0.05.
marrow donor group. Whereas, the MERw (the percentage of erythroblastic cells in white blood cells) and the MERm (the percentage of erythroblastic cells in mononuclear cells) were lower in peripheral blood from the bone marrow donor group than that in peripheral blood from inpatients pre- and post-HSCT (Table 3). The morphological characteristics of bone marrow were described by the bone marrow hyperplastic degree (BMHD) and number of erythroblastic islands. The bone marrow hyperplastic activity was examined in the donor group, pre-HSCT, and post-HSCT groups. The BMHD was low or extremely low in the pre-HSCT group. Ninety days after HSCT, it showed an elevation in hematopoietic activity (Table 3, Figure 1A). The MIQASs (Mean Islands Quantity In a Smear) of bone marrow erythroblastic islands (Table 3, Figure 1B) in the groups were as follows: the donor group (21.4 ± 4.5), the pre-HSCT group (3.2 ± 1.4), 30 days after HSCT (43.3 ± 4.1), 90 days after HSCT (46.2 ± 3.6), and 180 days after HSCT (44.7 ± 4.2). The MIQAS in the donor group was higher than that in the pre-HSCT group, but was less than that in post-HSCT groups. However, The MMCs and MERm in the bone marrow from bone marrow donor group were higher than that in the bone marrow from the pre- and post-HSCT groups (Table 3).

The Emp expression
Emp protein and mRNA expressions were detected in mononuclear cells from peripheral blood and bone marrow. Emp protein was not detected in peripheral blood pre-HSCT and post-HSCT groups. Emp protein was undetectable in bone marrow in pre-HSCT group, but was detected in post-HSCT group, and there is no difference between day 30, 90, and 180 post-HSCT groups (Figure 2A). Emp mRNA level was higher in Emp protein-positive bone marrow than that in Emp protein-negative bone marrow (P < 0.05) (Figure 2B). Furthermore, Emp mRNA levels in mononuclear cells from peripheral blood and bone marrow were significantly increased after HSCT (P < 0.05) (Figure 2C). Analysis of EPO treatment
In order to explore the correlation of Emp and erythroblastic island formation in bone marrow in patients with

**Figure 3 Emp expression after EPO treatment in bone marrow.** (A) The bone marrow island in one of 16 patients treated with EPO was shown under 100× (a), 400× (b), and 1,000 × (c) magnification. The larger arrow pointed to the macrophage and the smaller ones indicated erythroblasts. (B) The mean grey-scale ratio of Emp to β-actin protein (MGREAp) in groups without EPO treatment, or with EPO treatment for 30 and 90 days. These data are representative of three independent experiments. n = 3. *P < 0.05.
severe anemia treated with EPO. Before EPO treatment, the erythroblastic islands were barely found in bone marrow smears. After EPO treatment, the number of erythroblastic islands was dramatically increased in the bone marrow smear. (Table 2, Figure 3A). The Emp protein was undetectable in mononuclear cells from bone marrow in patients not treated with EPO. However, after EPO treatment the Emp protein was significantly increased in mononuclear cells from bone marrow, in accordance with enhanced island formation (Figure 3B).

Discussion

HSCT is a potentially curative therapy for a variety of hematological disorders and cancers of the blood or bone marrow, such as multiple myeloma or leukemia. Hematopoietic evaluation of the patients after HSCT is very important.

In humans, the functional unit for definitive erythropoiesis is the erythroblastic island, a multicellular structure composed of a central macrophage surrounded by developing erythroblasts. Erythroblast-macrophage interactions play a central role in the terminal maturation of erythroblasts [1,2,9]. Reconstitution and increase of erythroblastic islands in bone marrow was usually used as a marker for successful HSCT. Erythroblast-macrophage protein (Emp) was initially identified as a mediator of erythroblast-macrophage interactions during erythroid differentiation. The Emp protein [1,2,8,16,18] plays an important role in normal maturation process of erythroblastic cells in erythroblastic islands in bone marrow. More recent studies have shown that targeted disruption of Emp leads to abnormal erythropoiesis. Unfortunately, the involvement of Emp in HSCT remains uncertain. In this report, we showed that Emp protein levels were correlated with erythroblastic island formation in bone marrow.

Emp was expressed in a variety of hematopoietic (and indeed many non-hematopoietic) cells, including erythroblasts and macrophages [21]. However, Emp expression increased in erythroblasts when hematopoiesis took place in bone marrow (Table 3). Interestingly in this study, Emp mRNA was detected in all the groups, whereas the Emp protein was only detectable in bone marrow mononuclear cells in HSCT group (Figure 2C). These results suggested that Emp might be a potential marker for bone marrow hematopoietic evaluation.

EPO, a kind of hormone preventing erythroid progenitors’ apoptosis [22], had been widely used in clinics [22-24]. Erythroblastic islands were barely found in bone marrow smears before EPO therapy and were dramatically increased after EPO treatment (Table 2, Figure 3A). Meanwhile, Emp protein level was significantly increased in mononuclear cells from bone marrow in patients receiving EPO treatment (Figure 3B). The data indicate that Emp protein expression could have a close correlation with hematopoietic island formation in bone marrow.

Taken together, our findings provide that Emp protein expression in bone marrow has a close relation with hematopoietic island formation, which might be a potential marker for hematopoietic evaluation in clinic. Thus, our findings suggest that erythoblast island formation is likely an essential feature of erythropoiesis after HSCT. Future studies will be required to assess if Emp levels directly correlate with functional erythropoiesis in this model.

Conclusions

The Emp expression correlates with erythroblastic island formation and has an important function for bone marrow hematopoiesis. Based on our data, we suggest that the Emp is a potential biomarker for hematopoietic evaluation of HSCT patients.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

XM carried out the molecular genetic studies, statistical analysis, and drafted the manuscript. XS participated in the molecular genetic studies. FL carried out the immunoassays. GL performed the statistical analysis. LH conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgments

We thank Dr. ManKong for his technical assistance and Dr. Jianxin Yang for helpful discussion. This work was supported by Health Department Fund Project in Hubei Province (grant number CGX2008-2).

Published: 8 April 2013

Received: 27 August 2012 Accepted: 27 February 2013

References

1. Hanspal M, Hanspal JS: The association of erythroblasts with macrophages promotes erythroid proliferation and maturation: A 30-kD heparin-binding protein is involved in this contact. Blood 1994, 84:3494–3504.
2. Hanspal M, Smockova Y, Uong Q: Molecular identification and functional characterization of a novel protein that mediates the attachment of erythroblasts to macrophages. Blood 1998, 92:2940–2950.
3. Sadahira Y, Mori M: Role of macrophage in erythropoiesis. Pathol Int 1999, 49:841–848.
4. Chasis JA: Erythroblastic islands: specialized microenvironmental niches for erythropoiesis. CurrOpinHematol 2006, 13:137–141.
5. Gregory CJ, Eaves AC: Human marrow cells capable of erythropoietic differentiation in vitro: definition of three erythroid colony responses. Blood 1977, 49:855–866.
6. Gregory CJ, Eaves AC: Three stages of erythropoietic progenitor differentiation distinguished by a number of physical and biologic properties. Blood 1978, 51:527–537.
7. Zhang J, Socolovsky M, Gross AW, Lodish HF: Role of Ras signaling in erythroid differentiation of mouse fetal liver cells: functional analysis by a flow cytometry-based novel culture system. Blood 2003, 102:3938–3946.
8. Mohandas N, Chasis JA: The erythroid niche: molecular processes occurring within erythroblastic islands. Transfus Clin Biol 2010, 17:110–111.

9. Hanspal M: Importance of cell-cell interactions in regulation of erythropoiesis. CurrOpinHematol 1997, 4:142–147.

10. El Nemer W, Gane P, Colin Y, Bony V, Rahuel C, Galacteros F, Cartron JP, Le Van KC: The Lutheran blood group glycoproteins, the erythroid receptors for laminin, are adhesion molecules. J BioChem 1998, 273:16686–16693.

11. Southcott M, Tanner M, Anstee D: The expression of human blood group antigens during erythropoiesis in a cell culture system. Blood 1999, 93:4425–4435.

12. Parsons SF, Spring FA, Chasis JA, et al: Erythroid cell adhesion molecules Lutheran and LW in health and disease. BullClinHematol 1999, 12:729–745.

13. Sadahira Y, Yoshino T, Monobe Y: Very late activation antigen-4 Vascular celladhesion molecule-1 interaction is inved in the formation of erythroblastic islands. J Exp Med 1995, 181:411–415.

14. Mankelow TJ, Spring FA, Parsons SF, Brady RL, Mohandas N, Chasis JA, Anstee DJ: Identification of critical amino-acid residues on the erythroid intercellular adhesion molecule-4 (ICAM-4) mediating adhesion to alphavintegrins. Blood 2004, 103:1503–1508.

15. Lee G, Lo A, Short SA, Mankelow TJ, Spring F, Parsons SF, Yazdanbakhsh K, Mohandas N, Anstee DJ, Chasis JA: Targeted gene deletion demonstrates that cell adhesion molecule ICAM-4 is critical for erythroblastic island formation. Blood 2006, 108:2064–2071.

16. Soni S, Bala S, Gwynn B, Sahr KE, Peters LL, Hanspal M: Absence of erythroblast macrophage protein (Emp) leads to failure of erythroblast nuclear extrusion. J BioChem 2006, 281:20181–20189.

17. Fabriek BO, Poelklot WM, Viet RP, van der Schors RC, Lijtenberg AJ, Weaver LK, Geest C, Matsuno K, Moestrup SK, Dijkstra CD, van den Berg TK: The macrophage CD163 surface glycoprotein is an erythroblast adhesion receptor. Blood 2007, 109:5223–5229.

18. Soni S, Bala S, Gwynn B, Sahr KE, Peters LL, Hanspal M: Requirement for erythroblast-macrophage protein (Emp) in definitive erythropoiesis. Blood Cells Mol Dis 2008, 41:141–147.

19. Ding Y, Kantarci A, Badwey JA, Hasturf H, Malabanan A, Van Dyke TE: Phosphorylation of pleckstrinincreases proinflammatorycytokine secretion by mononuclear phagocytes in diabetes mellitus. J Immunol 2007, 179:654–654.

20. Koury MJ, Bondurant MC: Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990, 248:378–381.

21. Bala S, Kumar A, Soni S, Sinha S, Hanspal M: Emp is a component of the nuclear matrix of mammalian cells and undergoes dynamic rearrangements during cell division. BiochemBiophys Res Commun 2006, 342:1040–1048.

22. Arabul M, Gullulu M, Yilmaz Y, Eren MA, Baran B, Gui CB, Kocarnaz G, Dilek K: Influence of erythropoietin therapy on serum prohepcidin levels in dialysis patients. MedSciMonit 2009, 15:CR583–587.

23. Yao H, Ashihara E, Maekawa T: Supportive therapies for myeloid leukemia including blood transfusion and growth factors. Nippon Rinsho 2009, 67:1951–1957.

24. Cáceres W, Santiago K, Paulo L, Roman J: Anemia and infections in multiple myeloma: supportive therapy. BolAsoc Med P R 2009, 101:50–52.